Harrow Health, Inc.
NASDAQ:HROWDrug Manufacturers - Specialty & Generic
+$0.12 today
- Market cap
- $1.21B
- Beta
- 0.28
- P/E (TTM)
- -104.7
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.75M
HROW Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Harrow Health, Inc.NASDAQ: HROW
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $5.58M rose 13.8% year over year, behind the +25.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 12.4% from the prior quarter. Over 3 fiscal years it compounded at +75.1% a year.
Context
- Depreciation & amortization amounted to 7.2% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +13.8% toward the trailing-twelve-month pace of +25.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 19.68M USD
- Year-over-year change
- +35.4%
- 4-year CAGR
- +69.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.68M | +35.4% |
| FY2024 | 2024-12-31 | 14.54M | +17.8% |
| FY2023 | 2023-12-31 | 12.34M | +236.7% |
| FY2022 | 2022-12-31 | 3.67M | +53.0% |
| FY2021 | 2021-12-31 | 2.4M | — |
Depreciation & Amortization vs competitors
How HROW compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +25.1% is the 4th highest of 8, against a peer median of +20.2%.
- Depreciation & amortization amounts to 7.6% of revenue for HROW, versus a peer median of 20.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $411M USD | -4.2% | +3.6% | 7.7% | |
| LTM Sep 2026 | $23.14M USD | -12.7% | +33.7% | — | |
| LTM Mar 2026 | $20.35M USD | +25.1% | +75.1% | 7.6% | |
| LTM Mar 2026 | $4.63M USD | +20.2% | +27.0% | 8.9% | |
| LTM Sep 2026 | $2.91M USD | +66.6% | +77.3% | 0.4% | |
| LTM Mar 2026 | $2.45M USD | +41.2% | -1.9% | 32.1% | |
| LTM Mar 2026 | CHF 580.43K CHF | +27.3% | +22.2% | 115.2% | |
| LTM Mar 2026 | $119.64K USD | +3.7% | -17.0% | 35.9% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $42.29K USD | — | — | — |
| Peer median (excluding HROW) | — | +20.2% | +22.2% | 20.5% | |
Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (18.01M) | (14.09M) | (24.41M) | (17.48M) | (5.14M) |
| Depreciation & Amortization | 2.4M | 3.67M | 12.34M | 14.54M | 19.68M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.75M | 7.97M | 15.7M | 17.62M | 12.5M |
| Change in Working Capital | (253K) | (5.57M) | (7.14M) | (44.63M) | 185K |
| Accounts Receivables | (1.83M) | (1.86M) | (30.34M) | (80.23M) | 5.01M |
| Inventory | (255K) | (2.32M) | (4.33M) | 165K | (2.82M) |
| Accounts Payables | 1.73M | 933K | 31.8M | 37.5M | (4.61M) |
| Other Working Capital | 103K | (2.32M) | (4.26M) | (2.06M) | 2.6M |
| Other Non-Cash Items | 15.2M | 9.72M | 7.35M | 7.75M | 16.64M |
| Operating Cash Flow | 5.08M | 1.71M | 3.84M | (22.2M) | 43.86M |
| Capital Expenditures | (28.51M) | (7.77M) | (152.55M) | (38.67M) | (1.1M) |
| Acquisitions (Net) | 9.83M | 0 | 0 | 0 | (4.36M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 9.83M | 0 | 0 | 5.51M | 0 |
| Other Investing Activities | (36.55M) | 854K | (151.09M) | (37.08M) | (215K) |
| Investing Cash Flow | (18.69M) | (1.74M) | (152.55M) | (33.16M) | (5.46M) |
| Debt Repayment | 71.07M | 31.72M | 74.64M | 29.78M | 11.84M |
| Common Stock Issued | 0 | 22.66M | 64.52M | 0 | 467K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (127K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (19.12M) | (234K) | (12.63M) | (1.25M) | (25.04M) |
| Financing Cash Flow | 51.47M | 54.14M | 126.53M | 28.53M | (12.72M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.87M | 54.1M | (22.19M) | (26.84M) | 25.68M |
| Free Cash Flow | (23.43M) | (6.07M) | (148.71M) | (60.88M) | 42.76M |
Harrow Health, Inc.
NASDAQ:HROW
Intrinsic Alpha fair value
Locked
Current Price
$32.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.